In a welcome move, Dynavax Technologies saw its Relative Strength Rating improve from 64 to 74 on Tuesday.
IBD's unique RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks stacks up against all the other stocks in our database.
History shows that the best stocks typically have an RS Rating of over 80 as they begin their largest climbs. See if Dynavax Technologies can continue to show renewed price strength and clear that threshold.
When To Sell Stocks To Lock In Profits And Minimize Losses
While the stock is not near a proper entry right now, see if it is able to form and break out from a proper base.
Earnings grew 400% last quarter, up from 20% in the prior report. Revenue also increased, from 16% to 30%. Look for the next report on or around May 1.
The company holds the No. 17 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Catalyst Pharmaceuticals and GeneDx Holdings are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Rising Relative Strength?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
